Viral Hepatitis

You have full text access to this OnlineOpen article

Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection†

  1. Martin Lagging1,‡,*,
  2. Nina Langeland2,
  3. Court Pedersen3,
  4. Martti Färkkilä4,
  5. Mads Rauning Buhl5,
  6. Kristine Mørch2,
  7. Amar P. Dhillon6,
  8. Åsa Alsiö1,
  9. Kristoffer Hellstrand1,
  10. Johan Westin1,
  11. Gunnar Norkrans1

Article first published online: 1 FEB 2008

DOI: 10.1002/hep.22253

Issue

Hepatology

Hepatology

Volume 47, Issue 6, pages 1837–1845, June 2008

Additional Information

How to Cite

Lagging, M., Langeland, N., Pedersen, C., Färkkilä, M., Buhl, M. R., Mørch, K., Dhillon, A. P., Alsiö, Å., Hellstrand, K., Westin, J. and Norkrans, G. (2008), Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology, 47: 1837–1845. doi: 10.1002/hep.22253

Author Information

  1. 1

    Department of Infectious Diseases, Göteborg University, Göteborg, Sweden

  2. 2

    Department of Infectious Diseases, Haukeland University Hospital and Institute of Medicine, University of Bergen, Bergen, Norway

  3. 3

    Department of Infectious Diseases, University of Southern Denmark, Southern Denmark, Denmark

  4. 4

    Department of Gastroenterology, Helsinki University, Helsinki, Finland

  5. 5

    Department of Infectious Diseases, Aarhus University, Aarhus, Denmark

  6. 6

    Department of Histopathology, Royal Free Hospital, London, United Kingdom

  1. ‡

    fax: +46-31-41 12 56

*Department of Infectious Diseases, Göteborg University, Guldhedsgatan 10B, SE-413 46 Göteborg, Sweden

  1. †

    Potential conflict of interest: Dr. Lagging is a consultant for Schering-Plough, Roche, and Abbott.

Publication History

  1. Issue published online: 28 MAY 2008
  2. Article first published online: 1 FEB 2008
  3. Accepted manuscript online: 1 FEB 2008 12:00AM EST
  4. Manuscript Accepted: 23 JAN 2008
  5. Manuscript Received: 27 AUG 2007

Funded by

  • Swedish Society of Medicine
  • Swedish Medical Research Council
  • Swedish Society of Microbiology
  • Avtal om läkarutbildning och forskning (ALF) Funds. Grant Number: ALFGBG-3149
  • Roche affiliates in the Nordic region

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (377K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Masao Omata, Tatsuo Kanda, Ming-Lung Yu, Osamu Yokosuka, Seng-Gee Lim, Wasim Jafri, Ryosuke Tateishi, Saeed S. Hamid, Wan-Long Chuang, Anuchit Chutaputti, Lai Wei, Jose Sollano, Shiv Kumar Sarin, Jia-Horng Kao, Geoffrey W. McCaughan, APASL consensus statements and management algorithms for hepatitis C virus infection, Hepatology International, 2012, 6, 2, 409

    CrossRef

  2. 2
    Keizo Kato, Takeshi Yonezawa, Chizuko Tachibana, Hiroyuki Tachibana, Satoshi Watanabe, Yasushi Mandai, Rei Kashima, Kazushi Fukuda, Response-guided therapy based on reaction to the initial dose using administration of peginterferon α-2a alone or in combination with ribavirin in naïve patients with chronic hepatitis C of serotype 2 and high viral loads, Kanzo, 2012, 53, 1, 18

    CrossRef

  3. 3
    K. Rajender Reddy, Frederick Lin, Fabien Zoulim, Response-guided and -unguided treatment of chronic hepatitis C, Liver International, 2012, 32,
    Direct Link:
  4. 4
    Yasunori Yamaguchi, Akihiro Tamori, Yasuhito Tanaka, Shuji Iwai, Sawako Kobayashi, Hideki Fujii, Hiroyasu Morikawa, Atsushi Hagihara, Masaru Enomoto, Norifumi Kawada, Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2, Hepatology Research, 2012, 42, 6
    Direct Link:
  5. 5
    L. Restivo, R. Zampino, B. Guerrera, L. Ruggiero, L. E. Adinolfi, Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR, Journal of Viral Hepatitis, 2012, 19, 5
    Direct Link:
  6. 6
    Andres Duarte-Rojo, Elizabeth Jenny Heathcote, Jordan Jay Feld, ‘Easy to treat’ genotypes were not created equal: Can rapid virological response (RVR) level the playing field?, Journal of Hepatology, 2011, 55, 2, 466

    CrossRef

  7. 7
    Maya Gambarin-Gelwan, Ira M. Jacobson, Chronic hepatitis C genotype 2 and 3: Are we ready for personalized medicine?, Journal of Hepatology, 2011, 55, 3, 505

    CrossRef

  8. 8
    Stevan A. Gonzalez, Consensus Interferon: Tailored Therapy and the Impact of Adherence, Digestive Diseases and Sciences, 2011, 56, 3, 631

    CrossRef

  9. 9
    McKenzie C. Ferguson, Current Therapies for Chronic Hepatitis C, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011, 31, 1
    Direct Link:
  10. 10
    Å. Alsiö, A. Jannesson, N. Langeland, C. Pedersen, M. Färkkilä, M. R. Buhl, K. Mørch, J. Westin, K. Hellstrand, G. Norkrans, M. Lagging, Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection, European Journal of Clinical Microbiology & Infectious Diseases, 2011,

    CrossRef

  11. 11
    Thomas-Matthias Scherzer, Harald Hofer, Albert Friedrich Staettermayer, Karoline Rutter, Sandra Beinhardt, Petra Steindl-Munda, Heidrun Kerschner, Harald H. Kessler, Peter Ferenci, Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin, Journal of Hepatology, 2011, 54, 5, 866

    CrossRef

  12. 12
    Nanna Hansen, Niels Obel, Peer B Christensen, Mette Kjær, Alex L Laursen, Henrik B Krarup, Axel Møller, Poul Schlichting, Jens Bukh, Nina Weis, Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study, BMC Infectious Diseases, 2011, 11, 1, 177

    CrossRef

  13. 13
    Scott L. Friedman, Focus, Journal of Hepatology, 2011, 54, 5, 841

    CrossRef

  14. 14
    Yoshito Itoh, Takeshi Nishimura, Kanji Yamaguchi, Chihiro Yokomizo, Hideki Fujii, Masahito Minami, Yasuyuki Nagao, Yoshio Sumida, Hiroaki Hashimoto, Atsushi Umemura, Toshihide Shima, Takeshi Okanoue, Toshikazu Yoshikawa, Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy, Hepatology Research, 2011, 41, 12
    Direct Link:
  15. 15
    M. Lindh, B. Arnholm, A. Eilard, M. Färkkilä, K. Hellstrand, M. Lagging, N. Langeland, K. Mørch, S. Nilsson, C. Pedersen, M. R. Buhl, T. Wahlberg, R. Wejstål, J. Westin, G. Norkrans, Hepatitis C treatment response kinetics and impact of baseline predictors, Journal of Viral Hepatitis, 2011, 18, 6
    Direct Link:
  16. 16
    Olav Dalgard, Zbigniew Konopski, Franziskus Bosse, Berit Nordstrand, Per Sandvei, Lars Karlsen, Jon Florholmen, Astrid Rojahn, Rune Almaas, Steinar Skrede, Arne Eskesen, Bjørn Myrvang, Hepatitt C - utredning og behandling, Tidsskrift for Den norske legeforening, 2011, 131, 1, 2

    CrossRef

  17. You have free access to this content17
    Alessandra Mangia, Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients, Liver International, 2011, 31, 1
    Direct Link:
  18. 18
    M. Lindh, M. Lagging, M. Farkkila, N. Langeland, K. Morch, S. Nilsson, G. Norkrans, C. Pedersen, M. R. Buhl, J. Westin, K. Hellstrand, Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus, Journal of Infectious Diseases, 2011, 203, 12, 1748

    CrossRef

  19. 19
    Martin Lagging, Åsa Alsiö, Kristoffer Hellstrand, Gunnar Norkrans, Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection?, Journal of Hepatology, 2011, 54, 4, 835

    CrossRef

  20. You have free access to this content20
    Salvatore Petta, Antonio Craxì, Optimal therapy in hepatitis C virus genotypes 2 and 3 patients, Liver International, 2011, 31,
    Direct Link:
  21. 21
    Reiko Etoh, Fumio Imazeki, Tomoko Kurihara, Kenichi Fukai, Keiichi Fujiwara, Makoto Arai, Tatsuo Kanda, Rintaro Mikata, Yutaka Yonemitsu, Osamu Yokosuka, Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response, BMC Research Notes, 2011, 4, 1, 316

    CrossRef

  22. 22
    S. K. Tohra, S. Taneja, S. Ghosh, B. K. Sharma, A. Duseja, R. K. Dhiman, A. Das, Y. K. Chawla, Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C, Digestive Diseases and Sciences, 2011, 56, 8, 2449

    CrossRef

  23. 23
    Michael Manns, Stefan Zeuzem, Ajit Sood, Yoav Lurie, Markus Cornberg, Hartwig Klinker, Peter Buggisch, Martin Rössle, Holger Hinrichsen, Ismail Merican, Yaron Ilan, Stefan Mauss, Saif Abu-Mouch, Andryes Horban, Thomas H. Müller, Christoph Welsch, Rongdean Chen, Rab Faruqi, Lisa D. Pedicone, Heiner Wedemeyer, Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C, Journal of Hepatology, 2011, 55, 3, 554

    CrossRef

  24. 24
    Tatsuo Kanda, Fumio Imazeki, Ryosaku Azemoto, Yutaka Yonemitsu, Shigeru Mikami, Kazuhiko Kita, Motohide Takashi, Masahiko Sunaga, Shuang Wu, Shingo Nakamoto, Akinobu Tawada, Makoto Arai, Keizo Kato, Yu Yoshida, Yoshihiro Koma, Keiichi Fujiwara, Kenichi Fukai, Noriaki Suzuki, Osamu Yokosuka, Response to Peginterferon-alfa 2b and Ribavirin in Japanese Patients with Chronic Hepatitis C Genotype 2, Digestive Diseases and Sciences, 2011, 56, 11, 3335

    CrossRef

  25. 25
    Vincent Di Martino, Carine Richou, Jean-Paul Cervoni, Jose M. Sanchez-Tapias, Donald M. Jensen, Alessandra Mangia, Maria Buti, Frances Sheppard, Peter Ferenci, Thierry Thévenot, Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future, Hepatology, 2011, 54, 3
    Direct Link:
  26. 26
    C. Pedersen, Å. Alsiö, M. Lagging, N. Langeland, M. Färkkilä, M. Rauning Buhl, K. Mørch, J. Westin, P. Sangfelt, G. Norkrans, P. Brehm Christensen, Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection, Journal of Viral Hepatitis, 2011, 18, 4
    Direct Link:
  27. 27
    Samir R. Shah, Keyur Patel, Patrick Marcellin, Graham R. Foster, Michael Manns, Shyam Kottilil, Letha Healey, Erik Pulkstenis, G. Mani Subramanian, John G. McHutchison, Mark S. Sulkowski, Stefan Zeuzem, David R. Nelson, Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Patients With HCV Genotype 3, Clinical Gastroenterology and Hepatology, 2011, 9, 8, 688

    CrossRef

  28. 28
    Ahmad Amanzada, Armin Goralczyk, Federico Moriconi, Martina Blaschke, Inga-Marie Schaefer, David Thiel, Sabine Mihm, Giuliano Ramadori, Ultra-Rapid Virological Response, Young Age, Low γ-GT/ALT-Ratio, and Absence of Steatosis Identify a Subgroup of HCV Genotype 3 Patients Who Achieve SVR with IFN-α2a Monotherapy, Digestive Diseases and Sciences, 2011, 56, 11, 3296

    CrossRef

  29. 29
    Peter Derek Christian Leutscher, Martin Lagging, Mads Rauning Buhl, Court Pedersen, Gunnar Norkrans, Nina Langeland, Kristine Mørch, Martti Färkkilä, Simon Hjerrild, Kristoffer Hellstrand, Per Bech, Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C, Hepatology, 2010, 52, 2
    Direct Link:
  30. 30
    Y. Inoue, N. Hiramatsu, T. Oze, T. Yakushijin, K. Mochizuki, H. Hagiwara, M. Oshita, E. Mita, H. Fukui, M. Inada, S. Tamura, H. Yoshihara, E. Hayashi, A. Inoue, Y. Imai, M. Kato, T. Miyagi, A. Hohsui, H. Ishida, S. Kiso, T. Kanto, A. Kasahara, T. Takehara, N. Hayashi, Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses, Journal of Viral Hepatitis, 2010, 17, 5
    Direct Link:
  31. 31
    Mitchell L. Shiffman, HCV Response-Guided Therapy: Should Treatment Length Be Shortened or Extended?, Current Hepatitis Reports, 2010, 10, 1, 4

    CrossRef

  32. 32
    Moises Diago, Mitchell L. Shiffman, Jean-Pierre Bronowicki, Stefan Zeuzem, Maribel Rodriguez-Torres, Stephen C. Pappas, Andreas Tietz, David R. Nelson, Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin, Hepatology, 2010, 51, 6
    Direct Link:
  33. 33
    Olav Dalgard, Kristian Bjoro, Helmer Ring-Larsen, Hans Verbaan, In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials, European Journal of Gastroenterology & Hepatology, 2010, 22, 5, 552

    CrossRef

  34. 34
    Knut Stokkeland, Fereshte Ebrahim, Anders Ekbom, Increased Risk of Esophageal Varices, Liver Cancer, and Death in Patients With Alcoholic Liver Disease, Alcoholism: Clinical and Experimental Research, 2010, 34, 11
    Direct Link:
  35. 35
    Izumi Namiki, Shuhei Nishiguchi, Keisuke Hino, Fumitaka Suzuki, Hiromitsu Kumada, Yoshihito Itoh, Yusuhiro Asahina, Akihiro Tamori, Naoki Hiramatsu, Norio Hayashi, Masatoshi Kudo, Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009), Hepatology Research, 2010, 40, 4
    Direct Link:
  36. 36
    Jean-Michel Pawlotsky, More sensitive hepatitis C virus RNA detection: What for?, Journal of Hepatology, 2010, 52, 6, 783

    CrossRef

  37. 37
    V. Pattullo, N. C. Ravindran, T. Mazzulli, D. K. H. Wong, E. J. Heathcote, Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C, Journal of Viral Hepatitis, 2010, 17, 12
    Direct Link:
  38. 38
    Stefan Zeuzem, Fred Poordad, Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response, Current Medical Research and Opinion, 2010, 26, 7, 1733

    CrossRef

  39. 39
    F. F. POORDAD, Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2010, 31, 12
    Direct Link:
  40. 40
    A. MANGIA, O. DALGARD, N. MINERVA, H. VERBAAN, D. BACCA, H. RING-LARSEN, M. COPETTI, V. CARRETTA, V. PIAZZOLLA, R. COZZOLONGO, L. MOTTOLA, A. ANDRIULLI, Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon α-2b and ribavirin, Alimentary Pharmacology & Therapeutics, 2010, 31, 12
    Direct Link:
  41. 41
    Galia Askarieh, Åsa Alsiö, Paolo Pugnale, Francesco Negro, Carlo Ferrari, Avidan U. Neumann, Jean-Michel Pawlotsky, Solko W. Schalm, Stefan Zeuzem, Gunnar Norkrans, Johan Westin, Jonas Söderholm, Kristoffer Hellstrand, Martin Lagging, Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C, Hepatology, 2010, 51, 5
    Direct Link:
  42. 42
    Ashwani K. Singal, Bhupinder S. Anand, Tailoring Treatment Duration to 12 to 16 Weeks in Hepatitis C Genotype 2 or 3 With Rapid Virologic Response, Journal of Clinical Gastroenterology, 2010, 1

    CrossRef

  43. 43
    Donald M. Jensen, Treatment Duration for Genotypes 2 and 3, Journal of Clinical Gastroenterology, 2010, 44, 8, 527

    CrossRef

  44. 44
    Chung-Feng Huang, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu, A crossing in therapy for hepatitis C virus genotype 2 or 3: Increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration, Hepatology, 2009, 49, 4
    Direct Link:
  45. 45
    Yoshiaki Iwasaki, Yasushi Shiratori, Shuhei Hige, Shuhei Nishiguchi, Hitoshi Takagi, Morikazu Onji, Haruhiko Yoshida, Namiki Izumi, Yutaka Kohgo, Kyosuke Yamamoto, Nobuhiro Sato, Akitaka Shibuya, Hidetsugu Saito, Michio Sata, Kazuyuki Suzuki, Shuichi Kaneko, Mitsuhiko Moriyama, Masao Omata, A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan, Hepatology International, 2009, 3, 3, 468

    CrossRef

  46. 46
    G.L. Gaundong Mbéthé, J. Foucher, V. DeLedinghen, V.P. Couzigou, Éradication du virus de l’hépatite C après un traitement de cinq semaines, La Revue de Médecine Interne, 2009, 30, 10, 900

    CrossRef

  47. 47
    Stevan A Gonzalez, Emmet B Keeffe, Chronic hepatitis B and C: update on therapy, Future Virology, 2009, 4, 5, 437

    CrossRef

  48. 48
    David R. Nelson, Gary L. Davis, Ira Jacobson, Gregory T. Everson, Michael W. Fried, Stephen A. Harrison, Tarek Hassanein, Donald M. Jensen, Karen L. Lindsay, Norah Terrault, Nizar Zein, Hepatitis C Virus: A Critical Appraisal of Approaches to Therapy, Clinical Gastroenterology and Hepatology, 2009, 7, 4, 397

    CrossRef

  49. 49
    H. Nomura, Y. Miyagi, H. Tanimoto, H. Ishibashi, Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C, Journal of Viral Hepatitis, 2009, 16, 5
    Direct Link:
  50. 50
    Shuhei Nishiguchi, Namiki Izumi, Keisuke Hino, Fumitaka Suzuki, Hiromitsu Kumada, Yoshito Ito, Yasuhiro Asahina, Akihiro Tamori, Naoki Hiramatsu, Norio Hayashi, Masatoshi Kudo, JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C, Kanzo, 2009, 50, 11, 665

    CrossRef

  51. 51
    Nipaporn Pichetshote, Erik Groessl, Helen Yee, Samuel B. Ho, Optimizing the Dose and Duration of Therapy for Chronic Hepatitis C, Gut and Liver, 2009, 3, 1, 1

    CrossRef

  52. 52
    Catherine François, Sandrine Castelain, Gilles Duverlie, Dominique Capron, Eric Nguyen-Khac, Optimizing the treatment of chronic viral hepatitis C, Expert Review of Gastroenterology & Hepatology, 2009, 3, 6, 607

    CrossRef

  53. 53
    Susan J. Keam, Risto S. Cvetković, Spotlight on Peginterferon-α-2a (40 kD) Plus Ribavirin in the Management of Chronic Hepatitis C Mono-Infection†, BioDrugs, 2009, 23, 1, 63

    CrossRef

  54. 54
    Ming-Lung Yu, Wan-Long Chuang, Treatment of chronic hepatitis C in Asia: When East meets West, Journal of Gastroenterology and Hepatology, 2009, 24, 3
    Direct Link:
  55. 55
    Ivo W. Graziadei, Wolfgang Vogel, Treatment of patients infected with chronic hepatitis C genotype 2 and 3: More data, more questions?, Hepatology, 2009, 49, 2
    Direct Link:
  56. 56
    Fred Poordad, Nancy Reau, Viral-guided hepatitis C therapy, Current Hepatitis Reports, 2009, 8, 2, 66

    CrossRef

  57. 57
    Virginia Knight, William Sievert, When less may not be best—The challenge of individualising antiviral therapy for chronic hepatitis C infection, Journal of Gastroenterology and Hepatology, 2009, 24, 3
    Direct Link:
  58. 58
    P. Ferenci, Peginterferon and ribavirin in HCV: Improvement of sustained viral response, Best Practice & Research Clinical Gastroenterology, 2008, 22, 6, 1109

    CrossRef

  59. 59
    Olav Dalgard, Alessandra Mangia, Short treatment to patients with genotype 2 or 3, Hepatology, 2008, 48, 2
    Direct Link:
  60. 60
    Martin Lagging, Nina Langeland, Court Pedersen, Martti Färkkilä, Mads Rauning Buhl, Kristine Mørch, Amar P. Dhillon, Åsa Alsiö, Kristoffer Hellstrand, Johan Westin, Peer Christensen, Peter Leutscher, Gunnar Norkrans, Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection, Hepatology, 2008, 48, 2
    Direct Link:
  61. 61
    Alessandra Mangia, Leonardo Mottola, Angelo Andriulli, Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3,
    Direct Link:
  62. 62
    Stella Martínez, Jose María Sánchez-Tapias, Xavier Forns, Genotypes 2 and 3 Relapse and Non-Response,
    Direct Link:
  63. 63
    Jean-Michel Pawlotsky, Stéphane Chevaliez, Measuring Antiviral Responses,
    Direct Link:
  64. 64
    Kenneth Yan, Amany Zekry, Standard Therapy for Genotypes 2/3,
    Direct Link:
View Full Article (HTML) Get PDF (377K)